BHEL Q1 Results FY26: Q1 PAT Falls 115.47% to -₹455.50 Crore; Revenue Down 0.04% YoY

BHEL Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

BHEL Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

BHEL Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• BHEL clocked Q1 FY26 consolidated revenue of ₹5,486.91 crores vs ₹5,484.92 crores. 
• On the profit front, BHEL earned a consolidated loss of ₹455.50 crore in Q1 FY26. During FY25, the company’s loss stood at ₹211.40 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 115.47% YoY, and revenue fell 0.04% YoY. 
• As per the standalone figures, the quarterly loss of BHEL has increased by 114.05%, and revenue has decreased by 0.04% YoY.

BHEL Share Price Performance

On the opening bell of 6th August 2025, the shares of BHEL opened at ₹231.78 per share. However, the initial gains are wiped out as of now, and BHEL shares are trading at ₹225.50 per share, lower than their opening price. 

Considering the long-term performance, BHEL shares have yielded close to -25.94% returns in the past 1 year, and 5-year returns stand at 539.86%. Over the maximum timeframe, the BHEL share provided 1,174.29% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in BHEL shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY

Recent Articles

Best Penny Stocks for Long Term in India | Penny Stocks in 2025

Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY

Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY

Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY

BLS International Services Q1 Results FY26: Q1 PAT Soars 49.76% to ₹171.00 Crore; Revenue Up 44.23% YoY